Zimmer Biomet Holdings has seen its consensus analyst price target decrease slightly from $104.84 to $102.92, reflecting a cautious reassessment among market watchers. While updated product launches and strategic moves such as the FNA acquisition inspire long-term optimism, recent quarterly results have prompted analysts to temper their near-term outlook. Stay with us to learn how these evolving expectations could shape the narrative for Zimmer Biomet going forward and discover ways to track these important changes as they unfold.

Stay updated as the Fair Value for Zimmer Biomet Holdings shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Zimmer Biomet Holdings.

Recent analyst activity around Zimmer Biomet Holdings reflects a shift in sentiment following the company’s latest results, with a blend of cautious optimism and growing reservations about its near-term prospects. Here is a synthesis of the most notable commentary from research firms:

???? Bullish Takeaways

Stifel maintains a Buy rating, even after lowering their price target to $110 from $118. They highlight the company’s commercial and innovation progress, which they believe is not fully reflected in the current stock performance. The firm points to recent positive developments, such as progress on new launches and commercial execution, even as international and noncore business headwinds emerged this quarter.

BTIG also retains a Buy rating with a revised price target of $112 from $122. They emphasize Zimmer Biomet’s strengths relative to peers, noting that knee growth, while below Stryker, still outperformed Johnson & Johnson. New product launches have provided momentum, even if recent results fell short of expectations.

Stifel previously increased their target from $115 to $118 after encouraging feedback from orthopedic surgeons regarding new product launches, suggesting long-term growth potential is supported by positive adoption trends.

RBC Capital, while lowering their target to $111 from $115, keeps an Outperform rating and highlights attractive valuations and growth opportunities within the Medical Supplies & Devices sector. They observe neutral sentiment going into earnings, based on Zimmer Biomet’s organic growth expectations and sector positioning.

???? Bearish Takeaways

JPMorgan downgraded Zimmer Biomet to Neutral from Overweight, with a notable price target reduction to $100 from $115. The firm described the recent quarter as a “step backwards,” citing a mismatch between management guidance and underlying business trends, along with a reduced outlook for organic sales growth in 2025.

Goldman Sachs lowered their price target to $97 from $106 and maintains a Neutral rating. They note that the company’s organic growth of 5.0% missed management’s prior expectations and that 2025 is tracking to be the fourth consecutive year of top-line growth deceleration, despite progress on diversification.

Canaccord also reduced its target, now $93 from $101, and keeps a Hold rating. Their post-earnings review flagged tightened guidance and reaffirmed growth expectations, with acknowledgment of the positive FNA acquisition but an overall measured tone on near-term upside.

BTIG and Stifel, while maintaining Buy ratings, acknowledge that Q3 results were disappointing and below both peer performance and investor optimism, particularly following a strong Q2 and product launches.

Collectively, analyst perspectives reflect confidence in Zimmer Biomet’s execution around innovation and product pipelines. However, reservations remain centered on valuation, pace of growth, and the risk that recent headwinds may continue to weigh on near-term performance. Several firms have meaningfully lowered their price targets, underscoring a more cautious approach, even as longer-term opportunities are still recognized within the stock’s sector positioning and strategy execution.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!

The U.S. FDA has granted 510(k) clearance for ROSA Knee with OptimiZe, Zimmer Biomet's updated robotic-assisted knee system. This system is designed to improve surgical planning and enable more accurate implant placement.

The iTaperloc Complete and iG7 Hip System are the company's first products to receive the FDA Breakthrough Device Designation. This designation recognizes their iodine-treated implants aimed at reducing the risk of joint infection.

Zimmer Biomet has expanded its trauma solutions portfolio with the launch of new foot and ankle products. These include the Gorilla Pilon Fusion Plating System and Phantom TTC Trauma Nail, which are designed to address complex fracture care.

The company recently completed a share buyback program, repurchasing over 9 million shares for almost $980 million as part of its planned capital return to shareholders.

Consensus Analyst Price Target has decreased slightly, from $104.84 to $102.92 per share.

Discount Rate has edged down marginally, moving from 8.77% to 8.75%.

Revenue Growth projections have been reduced slightly, shifting from 4.79% to 4.78%.

Net Profit Margin expectations have declined marginally, from 14.11% to 14.09%.

Future P/E Ratio has decreased, moving from 20.23x to 19.87x.

Narratives are a smarter, more intuitive way to invest. A Narrative connects a company’s story—your perspective on its future—to financial forecasts and fair value. This lets you see both the “why” and the “what” behind every stock’s price. On Simply Wall St’s Community page, millions of investors use Narratives to make buy or sell decisions by directly comparing Fair Value and current price. Each Narrative is updated automatically with fresh news and results, helping you stay one step ahead.

If you want the full picture on Zimmer Biomet Holdings, read the original Narrative and get deep insights into:

Long-term growth drivers like aging demographics and advances in robotics, which are poised to elevate orthopedic care and boost recurring revenues

The operational improvements, strategic divestitures, and strong U.S. execution that are driving above-market share gains and improved cash flow

The risks that could derail momentum, including pricing pressures, regulatory hurdles for new technologies, and integration challenges from recent acquisitions

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ZBH.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com